New York: Johnson & Johnson (JNJ.N) recently revealed it had registered information for a COVID-19 vaccine boost to the United States (US) Food and Drug Administration (FDA) for immediate in adults above 18.
A booster delivers 94 per cent immunisation against COVID-19 symptoms and almost completed deflection against any severe symptoms, a late-stage study from J&J showcased.
Even though experts in the field question the necessity of boosters when people aren’t even fully vaccinated overall in the US and beyond, the US government released a statement for boosters in August to ensure protection from the highly transmissible variants COVID-19 that have emerged.
J&J won’t be the first to go through with this decision. Pfizer Inc. (PFE.N) has already rolled out boosters for the elderly, the immunocompromised and those who had been immunised with vaccines that showcase lesser efficacy, like SinoVac and CanSino, to fortify them.
J&J has plans to report their findings and data to more regulation committees, the World Health Organization (WHO) and other groups tasked with the analysing, accountability and risk management of vaccine rollouts.